Ahmad Sajjadi, MD, PhD, UCI Neurologist and UCI MIND faculty member, was quoted in Healthline regarding the recent announcement by FDA to delay the decision to approve Eli Lilly’s amyloid…
Read More
UCI MIND faculty member and UCI Neurologist, Ahmad Sajjadi, MD, PhD, awarded UCI Institute for Precision Health Pilot Award. Dr. Sajjadi will work with Tianchen Qian, PhD, a REC trainee…
Read More
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein…
Read More
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new…
Read More
Ahmad Sajjadi, MD, PhD, a UCI Neurologist and UCI MIND faculty member was interviewed live on NBC Los Angeles about the recent announcement that talk show host Wendy Williams…
Read More
The LA Times recently published a fairly negative appraisal of the construct of preclinical Alzheimer’s disease (AD). The article described the recent effort by an international committee to update diagnostic…
Read More
Biogen, the maker of aducanumab has announced that it will terminate the Phase 4 trial required by the FDA for aducanumab, the monoclonal antibody against beta amyloid that received accelerated…
Read More
The medications have not been widely tested in Black people with the disease, underscoring stark — and persistent — disparities ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford…
Read More
Black people know intrinsically about the myriad of life areas negatively impacted by the fact that the myth of white supremacy is baked into the foundations of all American institutions.…
Read More
In the first study of its kind in humans, researchers have discovered that it is safe to use sound waves fired into specific areas of the brain to open a…
Read More